130 related articles for article (PubMed ID: 11529846)
1. Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome.
Verstovsek S; Kantarjian H; Aguayo A; Manshouri T; Freireich E; Keating M; Estey E; Albitar M
Br J Haematol; 2001 Aug; 114(2):290-5. PubMed ID: 11529846
[TBL] [Abstract][Full Text] [Related]
2. Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia.
Brunner B; Gunsilius E; Schumacher P; Zwierzina H; Gastl G; Stauder R
J Hematother Stem Cell Res; 2002 Feb; 11(1):119-25. PubMed ID: 11847008
[TBL] [Abstract][Full Text] [Related]
3. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
Aguayo A; Kantarjian HM; Estey EH; Giles FJ; Verstovsek S; Manshouri T; Gidel C; O'Brien S; Keating MJ; Albitar M
Cancer; 2002 Nov; 95(9):1923-30. PubMed ID: 12404286
[TBL] [Abstract][Full Text] [Related]
4. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome.
Verstovsek S; Kantarjian H; Estey E; Aguayo A; Giles FJ; Manshouri T; Koller C; Estrov Z; Freireich E; Keating M; Albitar M
Leukemia; 2001 Aug; 15(8):1165-70. PubMed ID: 11480557
[TBL] [Abstract][Full Text] [Related]
5. Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Albitar M; Johnson M; Do KA; Day A; Jilani I; Pierce S; Estey E; Kantarjian H; Keating M; Verstovsek S; O'brien S; Giles FJ
Leukemia; 2007 Mar; 21(3):480-8. PubMed ID: 17215857
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome.
Verstovsek S; Estey E; Manshouri T; Giles FJ; Cortes J; Beran M; Rogers A; Keating M; Kantarjian H; Albitar M
Br J Haematol; 2002 Jul; 118(1):151-6. PubMed ID: 12100142
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome.
Lai R; Estey E; Shen Y; Despa S; Kantarjian H; Beran M; Maushouri T; Quackenbuch RC; Keating M; Albitar M
Cancer; 2002 Jan; 94(1):14-7. PubMed ID: 11815955
[TBL] [Abstract][Full Text] [Related]
8. Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes.
Alexandrakis MG; Passam FH; Pappa CA; Sfiridaki K; Tsirakis G; Damilakis J; Stathopoulos EN; Kyriakou DS
Leuk Res; 2005 Jan; 29(1):41-6. PubMed ID: 15541473
[TBL] [Abstract][Full Text] [Related]
9. Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications.
Musolino C; Alonci A; Bellomo G; Loteta B; Quartarone E; Gangemi D; Massara E; Calabrò L
Eur J Haematol; 2004 Jun; 72(6):416-9. PubMed ID: 15128420
[TBL] [Abstract][Full Text] [Related]
10. The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
Hock BD; McKenzie JL; Patton WN; Haring LF; Yang Y; Shen Y; Estey EH; Albitar M
Cancer; 2003 Oct; 98(8):1681-8. PubMed ID: 14534885
[TBL] [Abstract][Full Text] [Related]
11. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study.
Bernstein SH; Brunetto VL; Davey FR; Wurster-Hill D; Mayer RJ; Stone RM; Schiffer CA; Bloomfield CD
J Clin Oncol; 1996 Sep; 14(9):2486-94. PubMed ID: 8823327
[TBL] [Abstract][Full Text] [Related]
12. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.
Ma W; Kantarjian H; Bekele B; Donahue AC; Zhang X; Zhang ZJ; O'Brien S; Estey E; Estrov Z; Cortes J; Keating M; Giles F; Albitar M
Clin Cancer Res; 2009 Jun; 15(11):3820-6. PubMed ID: 19458051
[TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of serum thymidine kinase in primary myelodysplastic syndromes: relationship to development of acute myeloid leukaemia.
Musto P; Bodenizza C; Falcone A; D'Arena G; Scalzulli P; Perla G; Modoni S; Parlatore L; Valvano MR; Carotenuto M
Br J Haematol; 1995 May; 90(1):125-30. PubMed ID: 7786774
[TBL] [Abstract][Full Text] [Related]
14. Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is prognostic factor for disease progression.
Molica S; Vitelli G; Levato D; Giannarelli D; Vacca A; Cuneo A; Ribatti D; Digiesi G
Eur J Haematol; 2004 Jul; 73(1):36-42. PubMed ID: 15182336
[TBL] [Abstract][Full Text] [Related]
15. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
16. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650
[TBL] [Abstract][Full Text] [Related]
17. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
[TBL] [Abstract][Full Text] [Related]
18. High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome.
Verstovsek S; Estey E; Manshouri T; Keating M; Kantarjian H; Giles FJ; Albitar M
Leuk Lymphoma; 2001 Jul; 42(3):511-6. PubMed ID: 11699417
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.
Parker JE; Pagliuca A; Mijovic A; Cullis JO; Czepulkowski B; Rassam SM; Samaratunga IR; Grace R; Gover PA; Mufti GJ
Br J Haematol; 1997 Dec; 99(4):939-44. PubMed ID: 9432047
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome.
Albitar M
Acta Haematol; 2001; 106(4):170-6. PubMed ID: 11815714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
